Endo International returns Belbuca (buprenorphine) buccal film rights to BioDelivery Science International and withdraws from pain therapy development to focus on Xiaflex.

Endo International plc announced that it has entered into an agreement with its partner, BioDelivery Sciences International, Inc. (BDSI), to return the Belbuca (buprenorphine) buccal film product to BDSI. Specific financial terms of the agreement have not been disclosed and are not material to Endo. Endo will not have any future royalty or milestone payments to BDSI and BDSI is not obligated for any future royalty payments to Endo.

With the return of Belbuca to BDSI, Endo has a portfolio of established pain products that the Company believes no longer requires field sales promotion. As a result, Endo also announced that it is eliminating its 375-member U.S. Branded pain sales field force, which consisted of both full-time employees and contract sales representatives, as well as internal support to the promoted pain business unit. This will allow the Company to focus efforts and resources more fully on its core U.S. Branded assets, including Xiaflex in the approved indications and the cellulite development program. The Company's legacy pain portfolio products – including Opana ER and Percocet, among others will be managed as mature brands. Endo expects to realize cost savings, drive greater efficiency and enhance its operational focus with its newly realigned U.S. Branded segment.